MAP2K7 and thyroid gland carcinoma: The ERK kinase inhibition we observed and that has been described by others in thyroid carcinoma cells [24-26] can easily be explained by inhibition of receptor tyrosine kinases or the RAF1 or BRAF molecule in the RAF-MEK-ERK kinase cascade [19].